Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-08-10 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) by Zhengzhou Antu Bioengineering Co., Ltd. It specifies the date, time, location, and participation method for the meeting, which is an interactive investor presentation focused on discussing the company's half-year operating results and financial indicators. The document does not contain actual financial statements or detailed financial analysis but rather invites investors to attend and ask questions. This matches the definition of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically for the half-year period. The document length is short (1564 characters), and it is not merely announcing the release of a report but announcing the meeting to discuss the half-year results interactively. Therefore, the correct classification is Investor Presentation (IP).
2022-08-10 Chinese
安图生物关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the board's approval of the share buyback plan, the price limits, the number of shares repurchased, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but reports on the status and execution of the share repurchase. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2022-08-01 Chinese
安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle raised funds for cash management and the progress of such activities. It includes specifics about the types of cash management products (large certificates of deposit), amounts involved, sources of funds (public convertible bonds and non-public stock issuance), approval procedures, risk analysis, and financial impact. The document is lengthy (over 11,000 characters) and contains detailed financial data related to the use of raised funds, investment projects, and returns from cash management products. It is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not related to board changes, earnings releases, or legal proceedings. The content focuses on capital management activities related to fundraising proceeds, which fits the category of Capital/Financing Update (CAP).
2022-07-20 Chinese
安图生物关于公司及子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the receipt of medical device registration certificates for the company and its subsidiaries. It details the specific certificates obtained, their validity, and the intended use of the products. The document includes no financial data, no discussion of financial results, no management commentary on financial performance, and no regulatory or legal proceedings. It is a regulatory announcement about product certifications, not a financial report or management report. The document length is 2643 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-07-04 Chinese
安图生物关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the board's approval of a share buyback plan, the price limits, the total amount authorized, and the actual shares repurchased to date, including prices and total amounts paid. The document references regulatory compliance with stock exchange rules and provides updates on the repurchase activity. The content is focused on the company's transactions in its own shares rather than financial results, management changes, or other report types. The document length is short (1235 characters) and is a specific announcement about share repurchase progress, fitting the definition of a Transaction in Own Shares (POS) filing.
2022-07-01 Chinese
上海市锦天城律师事务所关于安图生物差异化分红法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of a differentiated dividend distribution by Zhengzhou Antu Bioengineering Co., Ltd. It discusses the company's share repurchase, dividend distribution plan, and the impact on ex-dividend price. The document is a legal opinion on a specific corporate action (differentiated dividend) and does not contain financial statements, audit results, or management reports. It is not an announcement of voting results or a proxy statement. It is not a regulatory filing or certification letter but a legal opinion related to dividend distribution. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document related to corporate actions and does not fit other more specific categories.
2022-06-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.